Study of NKT5097 for advanced solid tumors
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced cancer that cannot be removed by surgery and has spread to other parts of your body.
- You have tried at least one standard treatment and it no longer works or you couldn't tolerate it.
- You are age 18 or older and your daily activity level is fairly good (able to do light work or fully active).
- You do not have active brain metastases, serious heart or lung problems, or another active cancer that needs treatment.
- Willing to provide a tumor tissue sample and take oral medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This study tests a new medicine, PF-08032562, for people with advanced breast or colorectal cancer that has not responded to prior treatments. It aims to see if the drug is safe and can help shrink or slow the cancer.
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
This trial tests an investigational drug called TB511, either alone or with an immunotherapy, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if TB511 can help shrink or control the tumor.
This trial tests a new drug called GNC-077 for people with advanced breast cancer or other solid tumors that have spread. It aims to see if the drug is safe and effective.
Hear when a new HR+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.